Metformin-induced cholestatic hepatitis.
To report a case of metformin-induced cholestatic hepatitis. We present a detailed case report, including laboratory and biopsy findings. In addition, similar cases from the literature are reviewed. In a 68-year-old man with newly diagnosed diabetes mellitus, metformin therapy was begun. The dosage initially was 500 mg twice daily and later was increased to 850 mg twice a day. Four weeks after met-formin treatment was initiated, jaundice, pruritus, and liver enzyme abnormalities were noted. The patient underwent an extensive work-up, including a hepatitis screen, ultrasonography, magnetic resonance imaging, and endoscopic retrograde cholangiopancreatography, all of which showed normal findings. A liver biopsy revealed severe cholestasis and mild portal inflammation. Treatment with metformin was discontinued, and the liver enzymes normalized except for a persistently increased level of alkaline phosphatase, most likely related to a prolonged cholestatic effect of metformin. Although rare, metformin can be responsible for inducing liver damage, and patients and physicians should be aware of this side effect.